McKesson stock: Barclays raises price target to $1,235
Published on 11/19/2026 at 13:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSFresh analyst signal for McKesson
- Barclays analyst Glen Santangelo kept an Overweight rating on the shares.
- The revised target gives investors a new valuation reference from a major bank.
On November 17, Markets Insider reported that Barclays analyst Glen Santangelo raised the price target for McKesson from 1,000 US dollars to 1,235 US dollars. Barclays kept its Overweight rating on the shares.
Barclays resets its valuation reference
The target increase represents a substantial upward revision within Barclays' framework. The unchanged Overweight rating indicates that the bank's positive stance on McKesson remains in place alongside the higher target.
For investors, the update adds a fresh bank assessment to the recent stream of analyst attention around the pharmaceutical distributor. The target is expressed in US dollars, while the German-market quote below is shown in euros; the two figures therefore represent different market references and currencies.
McKesson stock traded at 987.10 euros on Lang & Schwarz at 13:16 CET on Thursday, November 19, 2026.
McKesson Corporation
- ISIN: US58155Q1031
- WKN: 893953
- Ticker: MCK
- Price: 987.10 euros on Lang & Schwarz, November 19, 2026, 13:16 CET
For the broader US market context, see the S&P 500 market overview.
More developments can be found in more news and analyses on McKesson stock.
